Alnylam Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: Annual Revenue Growth Compared

Biotech Giants: Alnylam vs. Lantheus Revenue Growth

__timestampAlnylam Pharmaceuticals, Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 201450561000301600000
Thursday, January 1, 201541097000293461000
Friday, January 1, 201647159000301853000
Sunday, January 1, 201789912000331378000
Monday, January 1, 201874908000343374000
Tuesday, January 1, 2019219750000347337000
Wednesday, January 1, 2020492853000339410000
Friday, January 1, 2021844287000425208000
Saturday, January 1, 20221037418000935061000
Sunday, January 1, 202318282920001296429000
Monday, January 1, 20242248243000
Loading chart...

Unleashing insights

Alnylam Pharmaceuticals vs. Lantheus Holdings: A Decade of Revenue Growth

In the competitive landscape of biotechnology and pharmaceuticals, Alnylam Pharmaceuticals, Inc. and Lantheus Holdings, Inc. have shown remarkable revenue growth over the past decade. Starting in 2014, Alnylam's revenue was a modest $50 million, but by 2023, it skyrocketed to nearly $1.83 billion, marking an impressive growth of over 3,500%. Meanwhile, Lantheus Holdings began with a revenue of approximately $302 million in 2014 and reached $1.3 billion by 2023, reflecting a growth of over 330%.

This data highlights the dynamic nature of the pharmaceutical industry, where innovation and strategic investments can lead to exponential growth. Alnylam's focus on RNA interference therapeutics and Lantheus's advancements in diagnostic imaging have been pivotal in their financial trajectories. As these companies continue to innovate, their revenue trends offer valuable insights into the future of healthcare technology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025